IL13RA2 and glioma: Together, these experiments indicate that de novo established aggressive glioma tumors expressing IL13RA2 are responsive to CAR T-cell therapy, and thus, are suitable for investigating responses and resistance of aggressive pediatric diffuse gliomas to targeted therapeutics in mice with fully competent immune system.